Skip to main content
SpringerLink
Log in

Dapagliflozin: no increased risk of acute liver injury or severe UTI complications

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Sponsorship for the two studies, medical writing support and the article-processing charge were provided by AstraZeneca.

Reference

  • Danysh HE, et al. Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Safety : 30 Dec 2022. Available from: URL: https://doi.org/10.1007/s40264-022-01262-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dapagliflozin: no increased risk of acute liver injury or severe UTI complications. Reactions Weekly 1940, 8 (2023). https://doi.org/10.1007/s40278-023-31866-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-31866-1

Search

Navigation